Director
Hedi Ben Brahim has been Chairman and CEO, and CEO of Transgene from 2021 to 2023. Hedi Ben Brahim joined the Company from Institut Mérieux where he was Vice-President for Immunotherapy since 2018. In this role, he was the Chairman of ABL Inc., a contract research & development, and contract biomanufacturing organization (CRO/CMO). Prior to joining the Institut Mérieux, he was General Manager at a subsidiary of Vallourec, a solutions provider to the energy sector. Hedi began his career in the public sector at the Ministry of the Economy, Action and Public Accounts, then at the Ministry of Social Affairs and Health. He is a graduate of the École Polytechnique and the École Nationale Supérieure des Mines de Paris.
Hedi Ben Brahim has been a Director of the Company since 2019.
Committee: Member of the Strategy Committee and of the ESG Committee
